Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 470

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 470
---
 $161,394, reflecting an increase of $70,844 compared to cash used of $90,550 for the year ended December31, 2023. The change was mainly attributed to purchases of fixed assets and changes in pledged cash. Net cash received in investing activities for the year ended December31, 2023, was $90,250, reflecting an increase of $105,120 (53.8%), compared to cash used of $195,370 for the year ended December31, 2022. The change was mainly attributed to changes in bank deposits during the year ended December31, 2023. Net Cash Provided by Financing Activities Over the period 2021 to 2024, Kadimastem raised approximately $17.3million in equity for the issuance of 2,150,844 Kadimastem Ordinary Shares. In the years 2021 to 2024, Kadimastem received grants from the BIRD Foundation, the Israel Innovation Authority and the Australian Innovation Authority totaling $2.65million. 251 Net cash provided by financing activities for the year ended December31, 2024, amounted to $89,270, representing a decrease of $2,311,803 compared to $2,401,073 for the year ended December31, 2023. This increase was primarily due to capital raised by Kadimastem and proceeds from a convertible loan during the year ended December31, 2023. Net cash provided by financing activities for the year ended December31, 2023, amounted to $2,328,073, representing an increase of $1,218,993, (109%), compared to $1,109,080 for the year ended December31, 2022. This increase was primarily due to capital raised by Kadimastem and proceeds from a convertible loan during the reporting period. During the twelve months ended December 2023, the cash flow from financing activities included the receipt of a convertible loan from its shareholders, Alpha and Mr.Julien Ruggieri, totaling $1.7million, of which $1.25million was received on December21, 2023, and $450,000 was received on April20, 2024. The material terms of the convertible loan agreement are summarized in Note 15.A. of the Kadimastem Financial Statements dated as of December31, 2024 included elsewhere in this proxy statement/prospectus. Financing Developments Recent Developments (January1, 2025